The social contract and human rights bases for promoting access to effective, novel, high-priced medicines

High prices can significantly restrict access to medicines and may have an impact on health equity. There is no clear understanding of what the social responsibilities and rights are of those involved in the development, production and distribution of medicines. This technical report explores how so...

Full description

Bibliographic Details
Main Authors: Lemmens, Trudo, Ghimire, Kanksha Mahadevia (Author), Perehudoff, Katrina (Author), Persaud, Navindra (Author)
Corporate Authors: Oslo Medicines Initiative, World Health Organization Regional Office for Europe
Format: eBook
Language:English
Published: Copenhagen, Denmark World Health Organization 2022, [2022]
Series:Oslo medicines initiative technical report
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02215nam a2200301 u 4500
001 EB002153145
003 EBX01000000000000001291271
005 00000000000000.0
007 tu|||||||||||||||||||||
008 230403 r ||| eng
020 |a 9789289058261 
100 1 |a Lemmens, Trudo 
245 0 0 |a The social contract and human rights bases for promoting access to effective, novel, high-priced medicines  |h Elektronische Ressource  |c Trudo Lemmens, Kanksha Mahadevia Ghimire, Katrina Perehudoff and Navindra Persaud 
260 |a Copenhagen, Denmark  |b World Health Organization  |c 2022, [2022] 
300 |a 1 PDF file (ix, 64 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
700 1 |a Ghimire, Kanksha Mahadevia  |e [author] 
700 1 |a Perehudoff, Katrina  |e [author] 
700 1 |a Persaud, Navindra  |e [author] 
710 2 |a Oslo Medicines Initiative 
710 2 |a World Health Organization  |b Regional Office for Europe 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Oslo medicines initiative technical report 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK587884  |3 Volltext 
082 0 |a 610 
082 0 |a 330 
520 |a High prices can significantly restrict access to medicines and may have an impact on health equity. There is no clear understanding of what the social responsibilities and rights are of those involved in the development, production and distribution of medicines. This technical report explores how social contract theories, the global public (health) goods discourse and international human rights can be employed to sketch the broad contours of the responsibilities and rights of key stakeholders - particularly governments and pharmaceutical companies. These three approaches ascertain that stakeholders have specific responsibilities to assist in increasing access to high-priced medicines, yet they remain vague about the precise nature of actions stakeholders should perform to promote access to medicines. This report builds particularly on international human rights, and identifies specific obligations that, if properly implemented, should contribute to better access to medicines